News | March 15, 2026
China’s NMPA approves Zydus-licensed anaemia drug Desidustat
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Subscribe To Our Newsletter & Stay Updated
